Editorial Note: This article was rewritten using Artificial Intelligence (AI) based on original, verified sources. The accompanying images were upscaled with the assistance of AI. Any resemblance of figures in the images to real persons is entirely coincidental. Brands and logos depicted are the property of their respective owners and do not imply official endorsement or affiliation.
A French consortium, spearheaded by the healthcare group URGO, has announced a significant milestone in regenerative medicine: the laboratory development of a living, cryopreserved artificial skin designed for medical grafting. This achievement, marking the conclusion of the five-year GENESIS project, involves key partnerships with the CNRS and the Claude Bernard Lyon 1 University.
A Potential Solution for Severe Wounds
The primary objective of the GENESIS project is to provide a viable alternative for patients suffering from severe wounds, particularly extensive burns. Current treatment standards often necessitate multiple surgical procedures to harvest healthy skin from the patient for autografts, a process that can be physically demanding and limited by the availability of healthy tissue.
The newly developed technology aims to revolutionize this approach by producing artificial skin composed of living cells in advance. This tissue is then cryopreserved, allowing it to be stored and readily available for hospital use. According to the research consortium, the key technical accomplishments include:
- Establishing a pharmaceutical-grade cell bank.
- Organizing these cells into a three-dimensional structure to ensure tissue durability.
- Perfecting a cryopreservation process that maintains cell viability and functionality after thawing.
Collaboration and Future Timeline
The project represents a major collaborative effort, uniting public and private expertise in cell biology, tissue repair, bioproduction, and numerical process modeling. While the research laboratory is based in Dijon, the involvement of Lyon-based institutions like the CNRS and the Laboratoire de biologie tissulaire et d’ingénierie thérapeutique at Lyon 1 University highlights the region’s pivotal role in French biomedical innovation.
Despite this scientific success, the consortium emphasizes that the technology remains in the pre-clinical stage. The development path forward is structured as follows:
| Phase | Target Date |
| First Clinical Trials | 2030 |
| Potential Commercialization | 2040 |
The next phase involves transitioning from laboratory design to industrial and clinical development. The initial clinical studies will utilize production facilities managed by the French Blood Establishment (Établissement français du sang). URGO must now focus on scaling up production capabilities while navigating rigorous regulatory and clinical safety requirements.
This breakthrough will be presented at the upcoming Choose France summit on November 23. It serves as a prime example of the ongoing effort in France to transform long-term academic research into scalable, industrial health products.
Source: Lyon Entreprises